The quarter reflected steady revenue growth but underscored challenges in profit conversion, as seen in declining operating ...

Q4 2024 Earnings Call Transcript February 13, 2025 DexCom, Inc. misses on earnings expectations. Reported EPS is $0.45 EPS, expectations were $0.4792. Operator: Thank you for standing by. My name is ...

DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts ...

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...

A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...

Reports Q4 revenue $1.11B, consensus $1.10B. “In 2024, we implemented our largest US commercial sales force expansion, had two major product ...

DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track ...

We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are ...

Stratos Wealth Partners LTD. purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 2,583 shares of the medical device ...

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...

Medical device company DexCom (NASDAQ:DXCM) reported Q4 CY2024 results topping the market’s revenue expectations, with sales ...